2022 What's Next for Asia-Pacific Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics Market?—Growth Opportunities in 18 Countries - Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Instrumentation Pipeline, Latest Te

2022 What's Next for Asia-Pacific Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics Market?—Growth Opportunities in 18 Countries - Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Instrumentation Pipeline, Latest Technologies, Market Barriers and Risks

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products for diagnosing genetic diseases, cancer, as well as forensic and paternity/HLA testing during the next five years.

Report Presents

- Market shares of leading suppliers
- Business and technological trends in major markets
- Five-year test volume and sales forecasts
- Feature comparison of major analyzers
- Strategic profiles of leading market players and start-up firms developing innovative products
- Specific product and business opportunities for instrument and consumable suppliers.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

- Business planning issues and concerns.

Countries Analyses

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam

Market Segmentation Analysis

Market Segmentation Analysis

Five-year test volume and sales forecasts for major applications, including:

- Forensic Testing
- Cancer
- Paternity Testing/HLA Typing
- Genetic Diseases
- Others

Product/Technology Review

- Comparison of major molecular diagnostic analyzers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and target/signal amplification methods.

- Worldwide listings of companies developing new molecular diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

- Abbott
- Affymetrix
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Cepheid/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Decode Genetics
- Diadexus
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Grifols
- Hologic
- Illumina
- LabCorp
- Leica Biosystems
- Li-Cor Biosciences
- Myriad Genetics
- Ortho-Clinical Diagnostics
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Shimadzu
- Siemens Healthineers
- Sierra Molecular
- Takara Bio
- Tecan Group
- Thermo Fisher

Rationale

Genetic Diseases, Cancer, Forensic and Paternity testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.